Dr. Reddys Laboratories has launched Levalbuterol Inhalation Solution,
USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a
therapeutic equivalent generic version of XOPENEX (levalbuterol
hydrochloride) inhalation solution in the US market on September 23,
2014, approved by the United States Food & Drug Administration
(USFDA). Real Time News & Trading Trends Keep Liking Epic Research Private Limited
Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+
For more information ✆ – 0731-6642300 or Visit http://www.epicresearch.co
No comments:
Post a Comment